Intellia Therapeutics Inc
NTLA
$136.57
+646.7% (1 year change)
$136.57
+646.7% (1 year change)
$9.34 Billion
The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.$16.54 - $202.73
The lowest and highst price in the last 52 weeks.-62.83x
The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.$0.00 (0.0%)
Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).| Market Cap | $9.34 Billion |
| Enterprise Value | $8.75 Billion |
| Dividend Yield | $0.00 (0.0%) |
| 1 Year Return | +646.7% |
| 52-Week High | $202.73 |
| 52-Week Low | $16.54 |
| Beta | 2.2 |
| Outstanding Shares | 68.2 Million |
| Avg 30 Day Volume | 1.91 Million |
| P/E Ratio | -62.83 |
| PEG | -138.79 |
| Earnings per Share | -$2.47 |
| Price to Sales Ratio | Infinity |
| Price to Book Ratio | 17.07 |
| Revenue to Enterprise Value | 169.91 |
| EBIT to Enterprise Value | -58.38 |
| Total Debt to Enterprise Value | 0.0 |
| Debt to Equity | 0.0 |
| Revenue | $51.5 Million |
| Gross Profit | $51.5 Million |
| EBIT | -$150 Million |
| Net Income | -$149 Million |
| Profit Margin | -288.47% |
| Quarterly Earnings Growth (YoY) | +45.3% |
| Return on Equity | -27.23% |
| Return on Assets | -20.73% |
| Return on Invested Capital | -22.85% |
Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. Intellia Therapeutics was founded in May 2014 to develop biopharmaceuticals using CRISPR.
CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRIS...
There are still some key unanswered questions for the biotech''s promising gene-editing therapy.
Intellia Therapeutics (NTLA) CEO John Leonard believes that gene-editing remedy may come to market very, very quickly, in response to an interview on CNBCs Closing Bell, after information broke tha...